Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine

OBJECTIVE: Evaluate the safety and tolerability of oral rimegepant when used for acute treatment concomitantly with a monoclonal antibody (mAb) targeting the calcitonin gene‐related peptide (CGRP) ligand or receptor (CGRP mAb) for the preventive treatment of migraine. BACKGROUND: The efficacy of CGR...

Descripción completa

Detalles Bibliográficos
Autores principales: Berman, Gary, Croop, Robert, Kudrow, David, Halverson, Philip, Lovegren, Meghan, Thiry, Alexandra C., Conway, Charles M., Coric, Vladimir, Lipton, Richard B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496574/
https://www.ncbi.nlm.nih.gov/pubmed/32799325
http://dx.doi.org/10.1111/head.13930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496574/
https://www.ncbi.nlm.nih.gov/pubmed/32799325
http://dx.doi.org/10.1111/head.13930

Ejemplares similares